UIC202502 + UIC202505

UIC202502 + UIC202505 appears to be a **combination therapy** under investigation, likely developed by Korea United Pharm, but there is no detailed public information about their active pharmaceutical ingredients, mechanisms of action, or clinical indications. Both are referenced in the same style as related compounds such as UIC201603 and UIC201604, which have been studied in pharmacokinetic combination studies in healthy volunteers. There is no evidence that UIC202502 or UIC202505 are approved pharmaceuticals or that their exact identity and targets are published in indexed biomedical literature or clinical trial databases[1].